Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
Eur Urol
    June 2018
  1. THOENY HC, Bellin MF, Comperat EM, Thalmann GN, et al
    Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients?
    Eur Urol. 2018 Jun 27. pii: S0302-2838(18)30442.
    >> Share

    May 2018
  2. PANEBIANCO V, Narumi Y, Altun E, Bochner BH, et al
    Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).
    Eur Urol. 2018 May 10. pii: S0302-2838(18)30335.
    >> Share

    April 2018
  3. MOSCHINI M, Sargos P
    Re: Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy a Randomized Phase 2 Trial.
    Eur Urol. 2018 Apr 9. pii: S0302-2838(18)30203.
    >> Share

  4. FABA OR, Breda A, Palou J
    Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2018 Apr 7. pii: S0302-2838(18)30243.
    >> Share

    March 2018
  5. SARFATY M, Hall PS, Chan KKW, Virik K, et al
    Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Eur Urol. 2018 Mar 22. pii: S0302-2838(18)30182.
    >> Share

  6. CUMBERBATCH MGK, Foerster B, Catto JWF, Kamat AM, et al
    Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol. 2018 Mar 6. pii: S0302-2838(18)30121.
    >> Share

    February 2018
  7. EL-ACHKAR A, Kassouf W
    Re: Propensity Score Analysis of Radical Cystectomy Versus Bladder-sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Eur Urol. 2018 Feb 14. pii: S0302-2838(18)30088.
    >> Share

    December 2017
  8. SAITO R, Kobayashi T, Ogawa O
    Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer.
    Eur Urol. 2017 Dec 20. pii: S0302-2838(17)31042.
    >> Share

  9. PANG KH, Noon AP
    Re: Radical Cystectomy (Bladder Removal) Against Intravesical BCG Immunotherapy for High-risk Non-muscle Invasive Bladder Cancer (BRAVO): A Protocol for a Randomised Controlled Feasibility Study.
    Eur Urol. 2017 Dec 19. pii: S0302-2838(17)31039.
    >> Share

  10. OOSTERLINCK W, Decaestecker K
    Re: Active Surveillance for Low-risk Nonmuscle Invasive Bladder Cancer (NMIBC): a Confirmatory and Resource Consumption Study from Bladder Cancer Italian Active Surveillance (BIAS) Project.
    Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31018.
    >> Share

  11. CUMBERBATCH MG, Catto JWF
    Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Dec 5. pii: S0302-2838(17)31007.
    >> Share

    November 2017
  12. ODDENS JR, de Reijke TM
    The Current State of Predicting Response on Bacillus Calmette-Guerin Treatment for Nonmuscle Invasive Bladder Cancer is Not Yet Useful for Patients but Attributes to Understanding Its Mechanisms of Action.
    Eur Urol. 2017 Nov 30. pii: S0302-2838(17)31006.
    >> Share

  13. CHOI W, McConkey D
    Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in The Cancer Genome Atl
    Eur Urol. 2017 Nov 23. pii: S0302-2838(17)30979.
    >> Share

  14. LINSCOTT JA, Smith AB, Sammon JD
    Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30971.
    >> Share

  15. ABUFARAJ M, Dalbagni G, Daneshmand S, Horenblas S, et al
    The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30840.
    >> Share

    October 2017
  16. MAIA MC, Grivas P, Agarwal N, Pal SK, et al
    Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30902.
    >> Share

    September 2017
  17. OHNO Y
    Re: Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Eur Urol. 2017 Sep 26. pii: S0302-2838(17)30780.
    >> Share

  18. BIRKENKAMP-DEMTRODER K, Christensen E, Nordentoft I, Knudsen M, et al
    Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis.
    Eur Urol. 2017 Sep 25. pii: S0302-2838(17)30775.
    >> Share

    August 2017
  19. LEOW JJ, Cole AP, Seisen T, Bellmunt J, et al
    Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA.
    Eur Urol. 2017 Aug 9. pii: S0302-2838(17)30640.
    >> Share

    July 2017
  20. BOSSCHIETER J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, et al
    Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30538.
    >> Share

    June 2017
  21. SAFIRI S, Ayubi E
    Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Expe
    Eur Urol. 2017 Jun 22. pii: S0302-2838(17)30503.
    >> Share

  22. GIACALONE NJ, Niemierko A, Shipley WU, Efstathiou JA, et al
    Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: A
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30502.
    >> Share

  23. BOSSCHIETER J, Vis AN, van der Poel HG, Moonen LM, et al
    Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
    Eur Urol. 2017 Jun 12. pii: S0302-2838(17)30494.
    >> Share

  24. POWLES T, Gomez de Liano A, Ackerman C
    Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First
    Eur Urol. 2017 Jun 9. pii: S0302-2838(17)30453.
    >> Share

  25. D'ANDREA D, Shariat SF
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    Eur Urol. 2017 Jun 6. pii: S0302-2838(17)30481.
    >> Share

  26. DYRSKJOT L, Reinert T, Algaba F, Christensen E, et al
    Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30475.
    >> Share

  27. PIETZAK EJ, Bagrodia A, Cha EK, Drill EN, et al
    Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30466.
    >> Share

  28. CHEVALIER MF, Bohner P, Pieraerts C, Lhermitte B, et al
    Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
    Eur Urol. 2017;71:854-857.
    >> Share

  29. WANG L, Sustic T, Leite de Oliveira R, Lieftink C, et al
    A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Eur Urol. 2017;71:858-862.
    >> Share

    May 2017
  30. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30455.
    >> Share

  31. SEISEN T, Cole AP, Trinh QD
    Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol. In press. http://doi.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30411.
    >> Share

  32. KULKARNI GS, Klaassen Z
    Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?
    Eur Urol. 2017 May 5. pii: S0302-2838(17)30338.
    >> Share

  33. BABJUK M
    Bladder Cancer in the Elderly.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30326.
    >> Share

  34. FONTEYNE V, Ost P, Bellmunt J, Droz JP, et al
    Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.
    Eur Urol. 2017 May 3. pii: S0302-2838(17)30230.
    >> Share

  35. COLLINS JW, Hosseini A, Adding C, Nyberg T, et al
    Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group.
    Eur Urol. 2017;71:723-726.
    >> Share

    April 2017
  36. SOUKUP V, Capoun O, Cohen D, Hernandez V, et al
    Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel
    Eur Urol. 2017 Apr 27. pii: S0302-2838(17)30323.
    >> Share

  37. GALSKY MD, Sfakianos JP, Ferket BS
    Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?
    Eur Urol. 2017 Apr 19. pii: S0302-2838(17)30292.
    >> Share

  38. BLACK PC
    Seeking the Molecular Truth in Bladder Cancer: Biology=Genomex(Transcriptome)2.
    Eur Urol. 2017 Apr 17. pii: S0302-2838(17)30286.
    >> Share

  39. SEILER R, Oo HZ, Tortora D, Clausen TM, et al
    An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
    Eur Urol. 2017 Apr 10. pii: S0302-2838(17)30232.
    >> Share

  40. SEILER R, Ashab HA, Erho N, van Rhijn BW, et al
    Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Eur Urol. 2017 Apr 5. pii: S0302-2838(17)30251.
    >> Share

  41. GAKIS G, Black PC, Bochner BH, Boorjian SA, et al
    Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.
    Eur Urol. 2017;71:545-557.
    >> Share

    March 2017
  42. CHOI W, Ochoa A, McConkey DJ, Aine M, et al
    Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Eur Urol. 2017 Mar 29. pii: S0302-2838(17)30175.
    >> Share

  43. BOKARICA P, Hrkac A, Gilja I
    Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.
    Eur Urol. 2017 Mar 6. pii: S0302-2838(17)30126.
    >> Share

  44. DY GW, Gore JL, Forouzanfar MH, Naghavi M, et al
    Global Burden of Urologic Cancers, 1990-2013.
    Eur Urol. 2017;71:437-446.
    >> Share

  45. BABJUK M, Bohle A, Burger M, Capoun O, et al
    EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Eur Urol. 2017;71:447-461.
    >> Share

    February 2017
  46. MAY M, Lebentrau S, Brookman-May SD
    Re: Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30107.
    >> Share

  47. COTTE J, Roupret M
    Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer.
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30106.
    >> Share

  48. MARQUES M, Real FX
    PIcKing on Fibroblast Growth Factor Receptors as Bladder Cancer Therapeutic Targets.
    Eur Urol. 2017 Feb 14. pii: S0302-2838(17)30087.
    >> Share

    January 2017
  49. ROTH B
    Re: Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures.
    Eur Urol. 2017 Jan 13. pii: S0302-2838(17)30012.
    >> Share

  50. GIACALONE NJ, Shipley WU, Clayman RH, Niemierko A, et al
    Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Eur Urol. 2017 Jan 9. pii: S0302-2838(16)30924.
    >> Share

  51. DE VERE WHITE R
    Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia.
    Eur Urol. 2017 Jan 7. pii: S0302-2838(16)30921.
    >> Share

  52. CHRISTENSEN E, Birkenkamp-Demtroder K, Nordentoft I, Hoyer S, et al
    Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Eur Urol. 2017 Jan 6. pii: S0302-2838(16)30920.
    >> Share

    December 2016
  53. SELINSKI S, Gerullis H, Otto T, Roth E, et al
    Ultra-slow N-Acetyltransferase 2 Is Associated with Recurrence-free Time in Bladder Cancer Patients.
    Eur Urol. 2016 Dec 28. pii: S0302-2838(16)30904.
    >> Share

    October 2016
  54. LIEDBERG F, Jancke G, Sorenby A, Kannisto P, et al
    Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
    Eur Urol. 2016 Oct 19. pii: S0302-2838(16)30713.
    >> Share

  55. NECCHI A, Giardiello D, Mariani L
    Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Eur Urol. 2016 Oct 6. pii: S0302-2838(16)30684.
    >> Share

    September 2016
  56. LUO HL, Chen YT, Cheng YT, Chiang PH, et al
    Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Can
    Eur Urol. 2016 Sep 26. pii: S0302-2838(16)30663.
    >> Share

  57. SEISEN T, Babjuk M, Roupret M
    Reply to Hao Lun Luo, Yen Ta Chen, Yuan Tso Cheng, and Po Hui Chiang's Letter to the Editor re: Re: Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for
    Eur Urol. 2016 Sep 22. pii: S0302-2838(16)30662.
    >> Share

    August 2016
  58. LONGO T, McGinley KF, Freedman JA, Etienne W, et al
    Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.
    Eur Urol. 2016 Aug 9. pii: S0302-2838(16)30463.
    >> Share

    July 2016
  59. SEISEN T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, et al
    Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephrourecterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
    Eur Urol. 2016 Jul 28. pii: S0302-2838(16)30419.
    >> Share

  60. ARENDS TJ, Witjes JA
    Reply to Slawomir Poletajew, Piotr Radziszewski, Juan Palou Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Baci
    Eur Urol. 2016 Jul 14. pii: S0302-2838(16)30395.
    >> Share

  61. POLETAJEW S, Radziszewski P, Palou J
    Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and Hi
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30394.
    >> Share

  62. BABJUK M
    Trends in Bladder Cancer Incidence and Mortality: Success or Disappointment?
    Eur Urol. 2016 Jul 11. pii: S0302-2838(16)30392.
    >> Share

  63. YANG Z, Li C, Liu H, Zhang X, et al
    Single-cell sequencing reveals variants in ARID1A, GPRC5A and MLL2 driving self-renewal of human bladder cancer stem cells.
    Eur Urol. 2016 Jul 4. pii: S0302-2838(16)30343.
    >> Share

  64. YOSSEPOWITCH O
    Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.
    Eur Urol. 2016;70:204.
    >> Share

    June 2016
  65. ALFRED WITJES J, Lebret T, Comperat EM, Cowan NC, et al
    Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
    Eur Urol. 2016 Jun 30. pii: S0302-2838(16)30290.
    >> Share

  66. ANTONI S, Ferlay J, Soerjomataram I, Znaor A, et al
    Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.
    Eur Urol. 2016 Jun 28. pii: S0302-2838(16)30280.
    >> Share

  67. HERMANS TJ, Mertens LS, van Rhijn BW
    Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides.
    Eur Urol. 2016;69:1156-7.
    >> Share

    May 2016
  68. MCKIERNAN J
    Bacillus Calmette-Guerin Failure in Non-muscle-invasive Bladder Cancer: One Size Does Not Fit All.
    Eur Urol. 2016 May 4. pii: S0302-2838(16)30033.
    >> Share

  69. WITJES JA
    Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-invasive Bladder Cancer: A Sign of Changing Tides.
    Eur Urol. 2016;69:963.
    >> Share

    April 2016
  70. CUMBERBATCH MG, Catto JW
    Micropapillary Variant Bladder Cancer: A Bad Apple or a New Fruit?
    Eur Urol. 2016 Apr 29. pii: S0302-2838(16)30066.
    >> Share

  71. NAITO S, Algaba F, Babjuk M, Bryan RT, et al
    The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Mus
    Eur Urol. 2016 Apr 22. pii: S0302-2838(16)30031.
    >> Share

  72. GRAY PJ, Efstathiou JA, Shipley WU
    Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study.
    Eur Urol. 2016;69:757-8.
    >> Share

  73. PICKARD R
    Is Robot-assisted Cystectomy Better than Open?--Nearing an Answer after a Decade of Use.
    Eur Urol. 2016;69:622-3.
    >> Share

  74. KHAN MS, Gan C, Ahmed K, Ismail AF, et al
    A Single-centre Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2016;69:613-21.
    >> Share

    March 2016
  75. GUO CC, Dadhania V, Zhang L, Majewski T, et al
    Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
    Eur Urol. 2016 Mar 14. pii: S0302-2838(16)00246.
    >> Share

  76. RENTSCH CA, Muller DC, Ruiz C, Bubendorf L, et al
    Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer.
    Eur Urol. 2016 Mar 4. pii: S0302-2838(16)00240.
    >> Share

  77. ROUPRET M
    Re: Finasteride Reduces the Risk of Bladder Cancer in a Large Prospective Screening Study.
    Eur Urol. 2016;69:537.
    >> Share

  78. SHIBING Y, Qiang W
    Re: Morgan Roupret, Marko Babjuk, Eva Comperat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Eur Urol. 2016;69:e49-50.
    >> Share

  79. ROUPRET M
    Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Roupret, Marko Babjuk, Eva Comperat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
    Eur Urol. 2016;69:e51-2.
    >> Share

  80. HAMILTON-REEVES JM, Bechtel MD, Hand LK, Schleper A, et al
    Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial.
    Eur Urol. 2016;69:389-92.
    >> Share

    February 2016
  81. MMEJE CO, Guo CC, Shah JB, Navai N, et al
    Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guerin Therapy: Implication for Clinical Trial Design.
    Eur Urol. 2016 Feb 24. pii: S0302-2838(16)00209.
    >> Share

  82. WILLIAMS SB, Kamat AM
    Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patien
    Eur Urol. 2016 Feb 10. pii: S0302-2838(16)00173.
    >> Share

  83. SYLVESTER R, Gontero P, Oddens J
    Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Surv
    Eur Urol. 2016 Feb 10. pii: S0302-2838(16)00175.
    >> Share

  84. SOAVE A, Rink M
    Words of Wisdom. Re: Vinflunine in Routine Clinical Practice for the Treatment of Advanced or Metastatic Urothelial Cell Carcinoma--Data from a Prospective, Multicenter Experience.
    Eur Urol. 2016;69:373-4.
    >> Share

  85. KAMAT AM, Urbauer DL
    Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201-2: The Goal: Individualized Bacillus Calmette-Guerin Therapy.
    Eur Urol. 2016;69:203.
    >> Share

  86. WITJES JA
    The Final Answer to the Question of Whether We Should Use a Single Postoperative Instillation of Chemotherapy After Resection of pTa and pT1 Bladder Tumors.
    Eur Urol. 2016;69:245-6.
    >> Share

  87. ZUIVERLOON TC, Zwarthoff EC
    Predicting Response to Intravesical Bacillus Calmette-Guerin Immunotherapy: Are We Moving Forward?
    Eur Urol. 2016;69:201-2.
    >> Share

  88. SATKUNASIVAM R, Santomauro M, Chopra S, Plotner E, et al
    Robotic Intracorporeal Orthotopic Neobladder: Urodynamic Outcomes, Urinary Function, and Health-related Quality of Life.
    Eur Urol. 2016;69:247-53.
    >> Share

  89. KAMAT AM, Briggman J, Urbauer DL, Svatek R, et al
    Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guerin.
    Eur Urol. 2016;69:197-200.
    >> Share

  90. SYLVESTER RJ, Oosterlinck W, Holmang S, Sydes MR, et al
    Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carci
    Eur Urol. 2016;69:231-44.
    >> Share

    January 2016
  91. BIRKENKAMP-DEMTRODER K, Nordentoft I, Christensen E, Hoyer S, et al
    Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
    Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00058.
    >> Share

  92. ARENDS TJ, Nativ O, Maffezzini M, de Cobelli O, et al
    Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Eur Urol. 2016 Jan 20. pii: S0302-2838(16)00057.
    >> Share

    December 2015
  93. KIM JH, Ku JH
    Re: Edwin E. Morales, Sonja Grill, Robert S. Svatek, et al. Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.08.029.
    Eur Urol. 2015 Dec 9. pii: S0302-2838(15)01174.
    >> Share

  94. OHLMANN CH, Stockle M
    Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3
    Eur Urol. 2015;68:1104-5.
    >> Share

    November 2015
  95. RESNICK MJ
    Variation in Bladder Cancer Spending: A Global Call to Action.
    Eur Urol. 2015 Nov 19. pii: S0302-2838(15)01084.
    >> Share

    October 2015
  96. LEAL J, Luengo-Fernandez R, Sullivan R, Witjes JA, et al
    Economic Burden of Bladder Cancer Across the European Union.
    Eur Urol. 2015 Oct 24. pii: S0302-2838(15)01005.
    >> Share

    September 2015
  97. SONPAVDE G, Pond GR, Bellmunt J
    Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer - At What Cost? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.08.039: Combination Chemotherapy as a
    Eur Urol. 2015 Sep 23. pii: S0302-2838(15)00909.
    >> Share

  98. SONPAVDE G, Nix JW
    The Neoadjuvant Paradigm for Development of Systemic Therapy and Precision Medicine for Bladder Cancer.
    Eur Urol. 2015 Sep 20. pii: S0302-2838(15)00912.
    >> Share

  99. LA VECCHIA C
    Finasteride and Bladder Cancer.
    Eur Urol. 2015 Sep 10. pii: S0302-2838(15)00858.
    >> Share

  100. ROSE TL, Milowsky MI
    A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer - At What Cost?
    Eur Urol. 2015 Sep 4. pii: S0302-2838(15)00784.
    >> Share

  101. DOBRUCH J, Daneshmand S, Fisch M, Lotan Y, et al
    Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.
    Eur Urol. 2015 Sep 4. pii: S0302-2838(15)00782.
    >> Share

    August 2015
  102. MORALES EE, Grill S, Svatek RS, Kaushik D, et al
    Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study.
    Eur Urol. 2015 Aug 27. pii: S0302-2838(15)00772.
    >> Share

  103. RENTSCH CA, Stenner F, Ruiz C, Bubendorf L, et al
    Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep.
    Eur Urol. 2015 Aug 13. pii: S0302-2838(15)00709.
    >> Share

  104. BLACK PC
    Fine-tuning Risk Stratification for Non-Muscle-invasive Bladder Cancer.
    Eur Urol. 2015 Aug 6. pii: S0302-2838(15)00693.
    >> Share

    July 2015
  105. PLIMACK ER, Dunbrack RL, Brennan TA, Andrake MD, et al
    Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2015 Jul 31. pii: S0302-2838(15)00613.
    >> Share

  106. AINE M, Eriksson P, Liedberg F, Hoglund M, et al
    On Molecular Classification of Bladder Cancer: Out of One, Many.
    Eur Urol. 2015 Jul 24. pii: S0302-2838(15)00666.
    >> Share

  107. CAMBIER S, Sylvester RJ, Collette L, Gontero P, et al
    EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    Eur Urol. 2015 Jul 22. pii: S0302-2838(15)00556.
    >> Share

  108. FROEHNER M, Koch R, Heberling U, Novotny V, et al
    Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2015 Jul 17. pii: S0302-2838(15)00564.
    >> Share

  109. NGUYEN DP, Scherr DS
    Reply to Farshad Pourmalek, Hamidreza Abdi, and Peter C. Black's Letter to the Editor re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol.
    Eur Urol. 2015 Jul 14. pii: S0302-2838(15)00558.
    >> Share

  110. POURMALEK F, Abdi H, Black PC
    Re: Daniel P. Nguyen, Bashir Al Hussein Al Awamlh, Xian Wu, et al. Recurrence Patterns After Open and Robot-assisted Radical Cystectomy for Bladder Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.02.003.
    Eur Urol. 2015 Jul 13. pii: S0302-2838(15)00559.
    >> Share

  111. GOFRIT ON
    Re: Long-Term Outcomes in Patients with Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233.
    Eur Urol. 2015;68:165-6.
    >> Share

  112. PALMA N, Morris JC, Ali SM, Ross JS, et al
    Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.
    Eur Urol. 2015;68:168-70.
    >> Share

    June 2015
  113. DE MARTINO M, Lucca I, Mbeutcha A, Wiener HG, et al
    Carbonic Anhydrase IX as a Diagnostic Urinary Marker for Urothelial Bladder Cancer.
    Eur Urol. 2015 Jun 29. pii: S0302-2838(15)00518.
    >> Share

  114. GIANNARINI G, Palumbo V, Ficarra V
    Words of Wisdom. Re: robotic intracorporeal orthotopic neobladder during radical cystectomy in 132 patients.
    Eur Urol. 2015;67:1191-2.
    >> Share

    April 2015
  115. HERR HW
    Reply from Author re: Peter C. Black. Narrowing the cystoscopy gap. Eur Urol 2015;67:609-10: A better transurethral resection--proved or not!
    Eur Urol. 2015;67:610-1.
    >> Share

  116. BLACK PC
    Narrowing the cystoscopy gap.
    Eur Urol. 2015;67:609-10.
    >> Share

  117. HERR HW
    Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors.
    Eur Urol. 2015;67:605-8.
    >> Share

    March 2015
  118. CHAN KG, Guru K, Wiklund P, Catto J, et al
    Robot-assisted radical cystectomy and urinary diversion: technical recommendations from the Pasadena Consensus Panel.
    Eur Urol. 2015;67:423-31.
    >> Share

  119. ARON M, Gill IS
    Robotic radical cystectomy: so far, so good--what next?
    Eur Urol. 2015;67:361-2.
    >> Share

  120. WILSON TG, Guru K, Rosen RC, Wiklund P, et al
    Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel.
    Eur Urol. 2015;67:363-75.
    >> Share

  121. NOVARA G, Catto JW, Wilson T, Annerstedt M, et al
    Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy.
    Eur Urol. 2015;67:376-401.
    >> Share

  122. YUH B, Wilson T, Bochner B, Chan K, et al
    Systematic review and cumulative analysis of oncologic and functional outcomes after robot-assisted radical cystectomy.
    Eur Urol. 2015;67:402-22.
    >> Share

    February 2015
  123. JONES RJ
    Making trials work in practice: please mind the gap.
    Eur Urol. 2015;67:250-1.
    >> Share

  124. VAN DER HEIJDEN MS, van Rhijn BW
    The molecular background of urothelial cancer: ready for action?
    Eur Urol. 2015;67:202-3.
    >> Share

  125. KIM PH, Cha EK, Sfakianos JP, Iyer G, et al
    Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
    Eur Urol. 2015;67:198-201.
    >> Share

    January 2015
  126. NAVAI N, Matin SF
    Words of wisdom. Re: A randomized trial of robot-assisted laparoscopic radical cystectomy.
    Eur Urol. 2015;67:173-4.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016